Addex Therapeutics
- Company typePublic
- Founded2002
- HeadquartersPlan-les-ouates, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Addex Therapeutics firmographics
Firmographics- Name
- Addex Therapeutics
- Legal name
- Addex Therapeutics Ltd
- Website
- https://addextherapeutics.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Addex Therapeutics industry classification
Industry- Product category
- Neurological Therapeutics
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Addex Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Plan-les-ouates
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Addex Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Partnership milestone payments: Addex receives milestone payments upon successful achievement of prespecified regulatory, clinical and commercial milestones from partners. For the GABAB PAM substance use disorder program with Indivior, Addex is eligible for payments up to USD 330 million plus tiered royalties on net sales from high single digits up to low double-digit.
- Royalty revenue: Tiered royalties on net sales from commercialized products developed by partners, currently in development stage with no commercialized products generating revenue yet.
- Research collaboration funding: Funding received from partners for research activities, including CHF 2.7 million from Indivior for GABAB PAM substance use disorder research collaboration extended until June 2024.
- Grant funding: Eurostars grant funding of €4 million for mGlu2 NAM program targeting mild neurocognitive disorder (COGNI+ project).
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Addex Therapeutics product offering
Product offeringCore offering
Addex Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops orally available small molecule allosteric modulators—both Positive Allosteric Modulators (PAMs) and Negative Allosteric Modulators (NAMs)—for the treatment of neurological and psychiatric disorders. The company's portfolio includes dipraglurant (mGlu5 NAM) for post-stroke and traumatic brain injury recovery, ADX71149 (mGlu2 PAM), partnered GABAB PAM programs for substance use disorder (Indivior) and chronic cough, and the muscarinic M4 PAM NTX-253 advanced via its Neurosterix spin-out for schizophrenia.
Product overview
Addex Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel small molecule allosteric modulators for neurological disorders. The company's core technology platform focuses on allosteric modulation, which offers advantages over traditional orthosteric drugs by providing greater selectivity and better modulatory control at disease-mediating receptors. The product portfolio includes: Dipraglurant (mGlu5 NAM) in development for post-stroke and traumatic brain injury recovery; ADX71149 (mGlu2 PAM) with rights recently regained for potential future development; a partnered GABAB PAM program with Indivior for substance use disorders; and an independent GABAB PAM program for chronic cough. Additionally, Addex holds a 20% equity interest in Neurosterix LLC, which is advancing NTX-253 (M4 PAM) for schizophrenia through Phase 1 studies.
Differentiator
Problem solved
Functional benefit
Products and services
- Dipraglurant (mGlu5 NAM) A metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) being developed for post-stroke sensorimotor recovery and traumatic brain injury recovery, intended for patients with neurological disorders where current therapies rely on retraining and physiotherapy with partial recovery taking six months or more.
- ADX71149 (mGlu2 PAM) A positive allosteric modulator of metabotropic glutamate receptor subtype 2, previously partnered for an epilepsy Phase 2a study, with rights recently regained by Addex for potential future development in CNS indications.
- GABAB PAM - Substance Use Disorder Program A gamma-aminobutyric acid subtype B receptor positive allosteric modulator (GABAB PAM) program partnered with Indivior PLC for substance use disorders, with Addex eligible for up to USD 330 million in milestone payments plus tiered royalties from high single digits to low double-digit on net sales.
- GABAB PAM - Chronic Cough Program An independent GABAB positive allosteric modulator program being developed by Addex for the treatment of chronic cough, including in idiopathic pulmonary fibrosis (IPF), aiming to deliver a best-in-class therapy with improved tolerability compared with off-label baclofen.
- NTX-253 (M4 PAM) A potent, selective, orally available positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia treatment, targeting dopamine signaling indirectly to avoid the metabolic, cognitive, and motor side effects of dopamine-receptor antipsychotics. Advanced by Neurosterix, in which Addex holds 20% equity.
Quantifiable outcome
- GABAB PAM demonstrated robust anti-tussive activity in non-human primate chronic cough model with efficacy similar to baclofen but better tolerability
- +3 more outcomes
Companies that use Addex Therapeutics
Customer profileSegments5 records
Ideal customer profiles3 records
Addex Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Addex Therapeutics partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- Sinntaxis ABcoreAddex entered option and collaboration agreement with Sinntaxis AB for exclusive license to intellectual property covering use of mGlu5 inhibitors for treatment of brain injury recovery.
- Neurosterix LLCcoreSpin-out company advancing portfolio of allosteric modulator programs including M4 PAM for schizophrenia (NTX-253 in Phase 1) and mGlu7 NAM for mood disorders. Addex retains 20% equity interest. Neurosterix raised $65 million Series A (led by Perceptive Advisors).
- Indivior PLCcoreIndivior holds worldwide rights to Addex's GABAB PAM program for addiction and is responsible for all development, manufacture and commercialization. Addex retains rights for indications outside addiction including cough, pain. Indivior has selected a GABAB PAM candidate and successfully completed IND enabling studies. Addex eligible for up to USD 330 million in milestones plus tiered royalties from high single digits to low double digits.
- COGNI+ Consortium (Eurostars)minorLed consortium receiving €4 million Eurostars grant for mGlu2 NAM program targeting mild neurocognitive disorder (mNCD). Partners from South Korea, Netherlands, and UK. Project aims to deliver clinical candidates for IND enabling studies.
- Neuromed (Prof. Ferdinando Nicoletti & Dr Giuseppe Battaglia)minorCollaboration to characterize and better understand effects of allosteric modulators of metabotropic glutamate receptors.
- University of Pavia / Mondino Foundation (Prof. Antonio Pisani)minorCollaboration to explore use of dipraglurant to treat rare genetic forms of dystonia, evaluating effects of chronic treatment in preclinical models.
- Medical College of Wisconsin (Prof. Jyoti Sengupta)minorCollaboration to evaluate pharmacology of GABAB receptor positive allosteric modulators in preclinical models of visceral pain during urinary bladder inflammation.
- Max Planck Institute (Prof. Michael Sereda)minorCollaboration to evaluate efficacy of GABAB receptor positive allosteric modulators in preclinical model of CMT1A, a rare peripheral neuropathy.
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)minorNIAAA collaborating with Addex to evaluate pharmacology of positive and negative allosteric modulators in preclinical models of alcohol use disorder.
- National Institute on Drug Abuse (NIDA)minorNIDA collaborating to evaluate allosteric modulators in preclinical models of drug abuse and addiction. Program received USD 5.3 million grant to fund Phase 1 and Phase 1b cocaine interaction study.
- Innosuisse (Swiss Innovation Agency)minorSwiss Innovation Agency providing grants to support Addex projects in collaboration with CHUV, University of Geneva, and Swiss Institute of Bioinformatics.
- The Michael J Fox Foundation for Parkinson's ResearchminorAwarded $1.8 million grant to fund continued clinical testing of dipraglurant for treatment of Parkinson's disease levodopa-induced dyskinesia.
- Dystonia Medical Research FoundationminorCollaboration to explore use of dipraglurant to treat dystonia, designing detailed development plan and regulatory path for Phase 2 clinical trial.
- Charcot Marie Tooth Association (CMTA)minorCollaboration to evaluate GABAB receptor PAMs in preclinical models of Charcot-Marie-Tooth 1A disorder.
- Swiss Institute of Bioinformatics (SIB)minorCollaboration to apply computational approaches including AI, deep learning and molecular modelling to identify new therapeutic indications for ADX10061.
Scale indicators14 records
Recent moves7 records
Expansion highlights5 records
Addex Therapeutics competitors and assessment
Company assessmentDirect peers
- Cerevel Therapeutics: Cerevel (acquired by AbbVie in 2024) developed positive allosteric modulators of muscarinic M4 receptors for schizophrenia — directly overlapping with Addex's NTX-253 M4 PAM program now at Neurosterix. Both pursue allosteric strategies targeting CNS GPCRs.
- Karuna Therapeutics: Karuna (acquired by BMS) developed xanomeline, an M1/M4 muscarinic agonist for schizophrenia, advancing the same receptor family as Addex's M4 PAM. Both target CNS muscarinic signaling via alternative mechanistic angles for schizophrenia.
- Sage Therapeutics: Sage develops novel CNS small molecules (GABA-A receptor modulators like Zurzuvae for depression). Directly comparable as a clinical-stage CNS biotech pursuing differentiated receptor modulation approaches.
- Axsome Therapeutics: Axsome is a CNS-focused commercial-stage biopharma with Auvelity for depression and other CNS pipeline programs. Comparable in clinical-stage CNS focus targeting underserved neurological and psychiatric indications.
- Biohaven Pharmaceutical: Biohaven develops CNS therapies including CGRP-targeting agents for migraine and other neuroscience pipeline programs. Comparable as a CNS-focused clinical-to-commercial stage biopharma targeting neurological conditions.
Broad incumbents
- Acadia Pharmaceuticals: Acadia is a commercial CNS specialty pharma with Nuplazid approved for Parkinson's disease psychosis — overlapping with Addex's dipraglurant Parkinson's levodopa-induced dyskinesia program. Acadia has deeper commercial CNS infrastructure and broader pipeline.
- Intra-Cellular Therapies: Intra-Cellular (acquired by J&J) developed Caplyta for schizophrenia and other CNS therapies. Comparable as a CNS-focused biopharma with novel mechanisms addressing psychiatric disorders — overlapping with Addex's schizophrenia and mood disorder programs.
Emerging players
- Tonix Pharmaceuticals: Tonix is a clinical-stage CNS biopharma focused on neurological and psychiatric disorders including PTSD, depression and chronic pain — directly overlapping with Addex's mGlu7 NAM PTSD/anxiety program.
- Mind Medicine (MindMed): MindMed is a clinical-stage neuropsychiatry company developing psychedelic-inspired therapies for anxiety, ADHD and substance use disorders. Overlaps with Addex's GABAB PAM substance use disorder and mGlu7 NAM anxiety programs.
- Neumora Therapeutics: Neumora is a clinical-stage neuroscience company developing precision therapies for brain diseases including depression and schizophrenia. Comparable as a well-funded CNS biotech pursuing novel mechanisms in overlapping indications with Addex's pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Addex Therapeutics social profiles
Digital presenceAddex Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Addex Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Addex Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Addex Therapeutics funding detail
Funding detailFunding overview
Funding rounds21 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Addex Therapeutics M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Addex Therapeutics
What does Addex Therapeutics do?
Addex Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops orally available small molecule allosteric modulators—both Positive Allosteric Modulators (PAMs) and Negative Allosteric Modulators (NAMs)—for the treatment of neurological and psychiatric disorders. The company's portfolio includes dipraglurant (mGlu5 NAM) for post-stroke and traumatic brain injury recovery, ADX71149 (mGlu2 PAM), partnered GABAB PAM programs for substance use disorder (Indivior) and chronic cough, and the muscarinic M4 PAM NTX-253 advanced via its Neurosterix spin-out for schizophrenia.
Is Addex Therapeutics a public or private company?
Addex Therapeutics is a public company. It is classified as public and is currently operating.
When was Addex Therapeutics founded?
Addex Therapeutics was founded in 2002. It employs 1 to 10 people.
Where is Addex Therapeutics based?
Addex Therapeutics is headquartered in Plan-les-ouates, Switzerland, in the Europe region.
How does Addex Therapeutics make money?
Four revenue lines are on record. Partnership milestone payments are the primary driver. The others are royalty revenue, research collaboration funding and grant funding.
Who are Addex Therapeutics's main competitors?
Direct peers on record are Cerevel Therapeutics, Karuna Therapeutics, Sage Therapeutics, Axsome Therapeutics and Biohaven Pharmaceutical. Broad incumbents are Acadia Pharmaceuticals and Intra-Cellular Therapies. Emerging players are Tonix Pharmaceuticals, Mind Medicine (MindMed) and Neumora Therapeutics.
Does Addex Therapeutics have an API?
No public API is recorded for Addex Therapeutics.
What industry is Addex Therapeutics in?
Addex Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its SIC code is 2836.